Australia's most trusted
source of pharma news
Posted 19 May 2022 PM
Janssen is encouraging Australians who suffer major depressive disorder (MDD) as well as their friends and family to share their stories with PBAC ahead of the upcoming July meeting.
The company's submission for Spravato, a nasal spray for depression, will be considered by the committee when it convenes over two days from 6 July.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.